Gabapentin Capsule
Product Images NDC 68071-5317

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68071-5317). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Jpg (68071 5317 1)

Gabapentin 300 mg capsules label from NuCare Pharmaceuticals, Inc., with product NDC 68071-5317-1, contains 100 capsules. The label includes directions to take one capsule three times daily, storage instructions at controlled temperature 68-77°F, and a warning to keep out of reach of children. Manufacturer details and barcode are also visible.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 01)

Chemical structure diagram of gabapentin, showing its molecular framework with cyclohexane ring and functional groups including amine and carboxylic acid.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 02)

Line graph showing mean pain scores over 8 weeks comparing placebo and gabapentin 3600 mg/day. The x-axis represents weeks from baseline to week 8, while the y-axis shows mean pain scores from 0 to 10. The chart indicates a 4-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 03)

A line graph showing mean pain scores over a 7-week period comparing placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The x-axis represents weeks, including a 3-week dose titration period and a 4-week fixed dose period, while the y-axis shows mean pain scores ranging from 0 to 10. Data points illustrate pain score trends for each treatment group over time.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 04)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) dosages across two studies. The y-axis shows percentage of responders from 0% to 100%. Study 1 shows 12% for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance markers denote p-values below 0.01 and 0.001.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 05)

A scatter plot chart showing the percentage difference on the vertical axis and daily dose in milligrams on the horizontal axis. It includes data points for three studies labeled as study a, study b, and study c. The daily doses shown are approximately 600, 900, 1200, and 1800 mg, with corresponding difference percentages ranging from about 7% to 18%. Each study is represented by a different marker style and color in the legend.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.